BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microdacyn® Wound Irrigation Solution, including expanded claims, clearance for multiple use, and additional packaging configurations. Under this new clearance, Microdacyn Wound Irrigation Solution can be used under the supervision of a healthcare professional for cleansing, irrigating, moistening, debridement and removal of foreign material including microorganisms from exudating and/or dirty wounds, acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post‑surgical wounds, first and partial thickness second degree burns, abrasions, minor irritations of the skin, diabetic foot ulcers, ingrown toe nails, grafted and donor sites, and exit sites, and for moistening and lubricating absorbent wound dressings.
Sonoma Pharmaceuticals, Inc.(SNOA)Earnings, Financials & Key Ratios
SNOA•NASDAQ
$1.23
Price updated Jul 7, 2026
AboutSonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.Show more
- Revenue$20M+36.7%
- EBITDA-$2M+35.0%
- Net Income-$3M+8.2%
- EPS (Diluted)-1.89+32.3%
- Gross Margin37.97%-0.7%
- EBITDA Margin-11.89%+52.4%
- Operating Margin-12.6%+51.5%
- Net Margin-16.26%+32.8%
- ROE-84.6%-29.1%
SNOA Price & Volume
Sonoma Pharmaceuticals, Inc. (SNOA) stock price & volume — 10-year historical chart
Loading chart...
Revenue Growth Fails To Offset Operating Losses
Investment Thesis • Updated 2026Q4
VerdictNegative
Growth:Accelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and dilution risk
Key Thesis Takeaways
- Sonoma Pharmaceuticals demonstrates accelerating top-line momentum with 48.1% year-over-year revenue growth in 2026Q4, yet the company remains fundamentally challenged by persistent operating losses and a lack of meaningful operating leverage.
- The erosion of the equity base to $3.1 million and a dwindling cash position of $2.4 million suggest significant liquidity risks that may necessitate further shareholder dilution.
- Investors should monitor the company's ability to stabilize working capital, which has historically caused cash flow volatility as large as $1.5 million in a single quarter.
Verdict Logic
the company's cash position has dwindled to $2.4 million, which is insufficient to support ongoing operations given the persistent net loss of $581,000 reported in 2026Q4.
SNOA Growth Metrics
Sonoma Pharmaceuticals, Inc. (SNOA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years7.62%
5 Years0.95%
3 Years13.74%
TTM36.68%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM8.16%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM40.75%
Return on Capital
10 Years-53.04%
5 Years-37.44%
3 Years-34.07%
Last Year-26.29%
SNOA Recent Earnings
Sonoma Pharmaceuticals, Inc. (SNOA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 2/12 qtrs (17%)
Q3 2026Latest
Jun 16, 2026Metric
Actual
Est
EPS
$0.09+62.5%
$0.24
Rev
$6M-0.1%
$6M
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$0.35-20.7%
$0.29
Rev
$4M-20.6%
$5M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.13+58.1%
$0.31
Rev
$6M+31.5%
$4M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.37+27.5%
$0.51
Rev
$4M-7.3%
$4M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 16, 2026 | $0.09vs $0.24+62.5% | $6Mvs $6M-0.1% |
| Q1 2026 | Feb 10, 2026 | $0.35vs $0.29-20.7% | $4Mvs $5M-20.6% |
| Q4 2025 | Nov 4, 2025 | $0.13vs $0.31+58.1% | $6Mvs $4M+31.5% |
| Q3 2025 | Aug 7, 2025 | $0.37vs $0.51+27.5% | $4Mvs $4M-7.3% |
Based on last 12 quarters of dataView full earnings history →
Latest SNOA News
Recent stock market news and headlines for Sonoma Pharmaceuticals, Inc. (SNOA)
Accesswire·Jun 30, 2026
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation SolutionAccesswire·Jun 16, 2026
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial ResultsRevenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025 United States revenues increased 194% in Q4 2026 compared to Q4 2025 and 117% in FY 2026 compared to FY 2025 Net loss improved 25% in Q4 2026 compared to Q4 2025, and 8% in FY 2026 compared to FY 2025 EBITDA loss improved 66% in Q4 2026 compared to Q4 2025, and 38% in FY 2026 compared to FY 2025 BOULDER, CO / ACCESS Newswire / June 16, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2026 and the fourth quarter ended March 31, 2026. "Fiscal 2026 was a year of significant progress for Sonoma," remarked Amy Trombly, CEO of Sonoma.
Peers Comparison
Key metrics vs top competitors for Sonoma Pharmaceuticals, Inc. (SNOA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.23 | $2.07M | -0.65 | 36.68% | -16.26% | -84.6% | — | |
| $0.12 | $705.41K | -0.09 | -8.54% | -21.13% | -360.33% | — | |
| $6.75 | $185.63M | -14.35 | 10.2% | -14.82% | -35.57% | — | |
| $0.08 | $360.49K | -0.04 | -35.82% | -709.4% | -453.74% | — | |
| $0.41 | $2.15M | -0.06 | -79.77% | -780.9% | — | — | |
| $0.37 | $3.35M | -0.24 | -10.3% | -3089.55% | -423.84% | — |
Compare SNOA vs Peers
Sonoma Pharmaceuticals, Inc. (SNOA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SNOA SEC Filings & Documents
Sonoma Pharmaceuticals, Inc. (SNOA) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Jun 18, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Apr 9, 2026·SEC
10-K Annual Reports
410-Q Quarterly Reports
6Get notified when SNOA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SNOA Frequently Asked Questions
Sonoma Pharmaceuticals, Inc. (SNOA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Sonoma Pharmaceuticals, Inc.'s revenue?
Sonoma Pharmaceuticals, Inc. (SNOA) reported $19.5M in revenue for fiscal year 2026. This represents a 1340% increase from $1.4M in 2005.
How fast is Sonoma Pharmaceuticals, Inc. growing?
Sonoma Pharmaceuticals, Inc. (SNOA) grew revenue by 36.7% over the past year. This is strong growth.
Is SNOA profitable?
Sonoma Pharmaceuticals, Inc. (SNOA) reported a net loss of $3.2M for fiscal year 2026.
Dividend & Returns
What is SNOA's return on equity?
Sonoma Pharmaceuticals, Inc. (SNOA) has a return on equity (ROE) of -84.6%. Negative ROE indicates the company is unprofitable.
What is Sonoma Pharmaceuticals, Inc.'s free cash flow?
Sonoma Pharmaceuticals, Inc. (SNOA) had negative free cash flow of $3.6M in fiscal year 2026, likely due to heavy capital investments.